Pfizer and BioNTech received first U.S. FDA Emergency Use Authorization of a COVID-19 vaccine booster
On Sept. 23, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) has authorized…
On Sept. 23, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) has authorized…
On Sept. 22, 2021, the Breakthrough Prize Foundation and its founding sponsors announced the 2022 winners of the…
On Sept. 20, 2021, Pfizer and BioNTech announced results from a Phase 2/3 trial showing a favorable safety…
On Sept. 6, 2021, Pfizer and BioNTech announced that they had submitted a variation to the European Medicines…
On Sept. 1, 2021, the World Health Organization inaugurated the new WHO Hub for Pandemic and Epidemic Intelligence…
On Aug. 26, 2021, Pfizer and BioNTech announced the signing of a letter of intent with Eurofarma Laboratorios,…
On Aug. 25, 2021, Pfizer and BioNTech announced the initiation of a supplemental Biologics License Application (sBLA) to…
On Aug. 23, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) approved the…
On Aug. 19, 2021, the University of Oxford reported that obtaining two vaccine doses remained the most effective…
On Aug. 16, 2021, Pfizer and BioNTech announced that they had submitted Phase 1 data to the U.S….
On Aug. 10, 2021, the National Institutes of Health (NIH) announced that a pilot study had begun to…
On Apr. 21, 2021, XPhyto announced that it had entered into an agreement with an established German pharmaceutical…
On Apr. 9, 2021, Pfizer announced they had requested amendments to the U.S. Emergency Use Authorization (EUA) of…
On Apr. 1, 2021, Pfizer and BioNTech announced updated topline results from analysis of 927 confirmed symptomatic cases…
On Feb. 26, 2021, Roche announced it had been granted special approval by the German Federal Institute for…
On Feb. 25, 2021, Pfizer and BioNTech announced they had begun an evaluation of the safety and immunogenicity…
On Feb. 19, 2021, the ACT Accelerator partnership welcomed over US$ 4.3 billion of new investments from the…
On Feb. 19, 2021, BioNTech announced the submission of new data to the FDA demonstrating the stability of…
On Feb. 18, 2021, Pfizer and BioNTech announced that the first participants hadbeen dosed in a global Phase…
On Feb. 17, 2021, BioNTech announced results from an in vitro study that provided additional data on the…
On Feb. 12, 2021, BioNTech announced that the U.S. government had exercised its option for an additional 100…
On Feb. 10, 2021, BioNTech announced they had increased their manufacturing capacity in Marburg, Germany to up to…
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
On Feb. 1, 2021, Pfizer and BioNTech announced that preclinical data in non-human primate and mouse models from…
On Jan. 29, 2021, Pfizer and BioNTech announced that data from an in vitro study on the capability…
On Jan. 27, 2021, Pfizer and BioNTech announced results from in vitro neutralization studies of sera from individuals…
On Jan. 22, 2021, COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for…
On Jan. 22, 2021, Pfizer and BioNTech announced an advance purchase agreement with COVAX for up to 40…
On Jan. 19, 2021, Pfizer and BioNTech announced that results from an in vitro study that provided additional…
On Jan. 15, 2021, Pfizer and BioNTech announced they had developed a plan that allowed the scale-up of…